Medable, Inc.

The industry remains unwavering in the commitment to increased clinical trial accessibility and representation. During SCOPE 2025, Pam Tenaerts, chief science officer (at the time of the interview) at Medable, took time out of her schedule to discuss the importance of representation in clinical trials to ensure medicines are effective for diverse populations. Tenaerts stresses that that inclusive trials enhance patient trust in medications. Key Takeaways The industry remains committed to maintaining high-quality, representative data from clinical trials. The industry is leaning more towards conducting clinical trials in locations where the target patient population is more prevalent, such as gastric carcinoma trials in Asia and melanoma trials in high sun exposure areas. Efforts are being made to include a wider network of clinical research sites, such as retail pharmacies and clinical practices, to improve patient access and representation. Reflecting the diversity of the patient population in clinical trials is important for building trust in the medications among both patients and clinicians. ALL COVERAGE Drug Development SCOPE Summit 2025 Key Takeaways: A Look Inside, Outside and Beyond the Cybersecurity Wall Jay Ferro, EVP, CIO, CPO & CTO at Clario discusses safety, trust and what keeps him up at night. February 13, 2025 · 1 min read · Lori Ellis Drug Development Healthcare at a Crossroads: Maintaining Good Science in Uncertain Times Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity. February 17, 2025 · 1 min read · Lori Ellis Drug Development Site Survival: Why Clinical Research Sites Need a Lifeline Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials. February 19, 2025 · 1 min read · Lori Ellis Drug Development Diversity at the Forefront: Life Sciences Industry Champions Inclusive Representation The industry remains unwavering in the commitment to increased clinical trial accessibility and representation. February 25, 2025 · 1 min read · Lori Ellis Drug Development Beyond Dr. Google: The Roles of Industry and AI in Fighting Misinformation and Fueling Patient Empowerment As communication gaps in the US healthcare market widen, the emphasis on the need for credible information and patient empowerment is paramount. February 27, 2025 · 1 min read · Lori Ellis Drug Development Building Patient Trust Amid an Environment of Distrust While at SCOPE 2025, Sam Srivastava, CEO at WCG Clinical discusses the challenges and responsibilities of the life sciences industry in building public trust amidst growing anger towards healthcare. February 28, 2025 · 1 min read · Lori Ellis Drug Development The Chilling Effect: State Actions, Patient Data Vulnerability, and DEI Uncertainty In the current legal and political landscape, it is all about survival for DEI initiatives. March 3, 2025 · 1 min read Drug Development Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025. March 5, 2025 · 1 min read · Lori Ellis

Remote patient monitoring company Withings Health Solutions, the professional healthcare division of Withings, announced that its BPM Pro 2 cellular blood pressure monitor has been cleared by the FDA. The BPM Pro 2, which Withings released in October, is designed to measure blood pressure and pulse rate in adults with arm circumferences of 9 to 17 inches (22 cm to 42 cm) or 16 to 20 inches (40 to 52 cm). It also permits care teams to scale remote patient monitoring and streamline operations by addressing a critical challenge in remote care, such as ensuring patients take more reliable at-home blood pressure measurements under prime conditions and supplying them with outcomes reported by the patient. It includes a color screen that regularly educates patients on how to take the measurements properly, while adding a new level of insight and precision. Questions can be asked to patients on the device's screen to capture information about symptoms and medication adherence through the Patient Insights feature. Additionally, the Retake Measure feature reminds patients to retake a BP reading if the results exceed predetermined thresholds, which the company says can help reduce follow-up calls and ensure measurement reliability. Care team members also have the ability to send personalized messages, reminders and motivational support to the patient's device. "We are thrilled BPM Pro 2 is now FDA-cleared, this device marks a significant advancement in remote patient monitoring," Antoine Robiliard, vice president of Withings Health Solutions, said in a statement. "BPM Pro 2 not only delivers precise, clinically meaningful blood pressure and pulse rate measurements but also empowers care teams with real-time insights and direct patient engagement tools. This milestone, along with the recognition as a CES 2025 Innovation Awards Honoree, underscores our commitment to creating solutions that streamline workflows, enhance patient involvement, and set new standards for the quality and reliability of remote care." THE LARGER TREND In September, the company secured FDA clearance for its Sleep Rx Mat, a contactless device designed to diagnose sleep apnea at home. The Sleep Rx Mat provides detailed analysis of sleep, breathing and cardiovascular activity throughout the night. Last year, Withings launched U-Scan, a biomarker assessment platform that can be placed inside a toilet bowl to monitor an individual's health using urine analysis. U-Scan is a reader with changeable analysis cartridges that analyzes urine for specific biomarkers and sends insights to the Withings Health Mate app daily. In 2022, Withings unveiled Sleep Analyzer, an under-the-mattress sleep-tracking mat designed to detect sleep apnea. That same year, Medable partnered with Withings Health Solutions to use the company's connected devices for decentralized clinical trials. The partnership allowed Withings' tools for remote monitoring, including connected scales, blood pressure monitors and sleep-tracking mats, to gather patient data and combine with Medable's clinical trial platform.

Remote patient monitoring company, Withings Health Solutions, a division of Withings, announced the release of BPM Pro 2, a cellular blood pressure monitor. The blood pressure monitor includes a Patient Insights feature that aims to simplify clinical workflows by collecting critical data via the device, including symptoms and medication adherence. Additionally, care teams have the capability to send patients customized messages and reminders. Data is immediately synced through cellular connectivity that allows healthcare partners to access the patient-generated data via their personal clinical platform or Withings proprietary patient-monitoring platform. It also offers WiFi and Bluetooth connectivity options. In addition to measuring heart rate and blood pressure, BPM Pro 2 is intended to have a future ability to take a 1-lead ECG to detect atrial fibrillation. According to the company, the portable device is compact and user-friendly. It supports two cuff sizes (9 to 17 inches and 16 to 21 inches), and displays blood pressure readings and other information in bold text, and in color. The device also includes a symptom-tracking feature whereby patients are asked customized questions to capture information like symptoms, medication adherence and sleep patterns. It can be structured to automatically cue patients to retake their blood pressure if it reaches a specific predetermined threshold. The device will be available in November, when the company expects FDA clearance. "At-home blood pressure monitoring has become a standard across the industry for managing chronic conditions like hypertension and heart failure but poses a real challenge in making sure the data collected is consistent, reliable, and actionable for care teams," Aline Criton, chief clinical and regulatory affairs officer at Withings, said in a statement. "Elevated readings may result from simple factors like improper rest before a measurement or signal more serious issues such as the start of a hypertensive crisis. BPM Pro 2 addresses these challenges with advanced features that enhance data reliability, and provide contextual patient insights that help care teams differentiate between routine variations and critical health events allowing for more timely and personalized care intervention." THE LARGER TREND In September, Withings secured FDA clearance with Sleep Rx Mat, a contactless device designed to diagnose sleep apnea at home. Sleep Rx Mat provides detailed analysis of sleep, breathing and cardiovascular activity all through the night. Last year, the company launched U-Scan, a biomarker assessment platform that can be put inside a toilet bowl to monitor someone's health via urine analysis. U-Scan is a reader with changeable analysis cartridges that examines urine for specific biomarkers and forwards insights to the Withings Health Mate app daily. In 2022, Withings unveiled Sleep Analyzer, an under-the-mattress sleep-tracking mat designed to detect sleep apnea. That same year, Medable partnered with Withings Health Solutions to use the company's connected devices for decentralized clinical trials. The alliance allowed Withings' tools for remote monitoring, like connected scales, blood pressure monitors and sleep-tracking mats, to gather patient data and combine with Medable's clinical trial platform.